These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 20167988)

  • 1. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T; Nemcová J; Vanecek T; Jindra P; Hes O; Bouda M; Treska V
    Antivir Ther; 2010; 15(1):23-30. PubMed ID: 20167988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T; Kacer M; Jindra P; Hes O; Lysak D; Bouda M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):294-304. PubMed ID: 25424991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.
    Reischig T; Hribova P; Jindra P; Hes O; Bouda M; Treska V; Viklicky O
    J Am Soc Nephrol; 2012 Sep; 23(9):1588-97. PubMed ID: 22917575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
    Reischig T; Opatrný K; Treska V; Mares J; Jindra P; Svecová M
    Kidney Blood Press Res; 2005; 28(4):218-25. PubMed ID: 16043964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients.
    Verghese PS; Evans MD; Hanson A; Hathi J; Chinnakotla S; Matas A; Balfour HH
    J Clin Virol; 2024 Jun; 172():105678. PubMed ID: 38688164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
    Kacer M; Kielberger L; Bouda M; Reischig T
    Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six months anti-viral prophylaxis significantly decreased cytomegalovirus disease compared with no anti-viral prophylaxis following renal transplantation.
    Leone F; Akl A; Giral M; Dantal J; Blancho G; Soulillou JP; Cantarovich D
    Transpl Int; 2010 Sep; 23(9):897-906. PubMed ID: 20230540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients.
    Reischig T; Prucha M; Sedlackova L; Lysak D; Jindra P; Bouda M; Matejovic M
    Antivir Ther; 2011; 16(8):1227-35. PubMed ID: 22155904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
    N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation.
    Reischig T; Jindra P; Hes O; Svecová M; Klaboch J; Treska V
    Am J Transplant; 2008 Jan; 8(1):69-77. PubMed ID: 17973956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.
    Ljungman P; de La Camara R; Milpied N; Volin L; Russell CA; Crisp A; Webster A;
    Blood; 2002 Apr; 99(8):3050-6. PubMed ID: 11929799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients.
    Kielberger L; Bouda M; Jindra P; Reischig T
    Kidney Blood Press Res; 2012; 35(6):407-16. PubMed ID: 22584353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
    Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA
    Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C; Rostaing L; Weclawiak H; Rossignol C; Kamar N; Izopet J
    J Med Virol; 2015 May; 87(5):836-44. PubMed ID: 25655981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
    Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
    Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.